

# Taiwanese new direction in prediction of early pregnancy preeclampsia: a prospective and non-interventional study

**Yen-Tin Chen**

Chang Gung Memorial Hospital

**Tzu-Yi Lin**

Chang Gung Memorial Hospital

**Po-Jen Cheng**

Chang Gung Memorial Hospital

**Kok-Seong Chan**

Chang Gung Memorial Hospital

**Hui-Yu Huang**

Chang Gung Memorial Hospital

**Steven W. Shaw** (✉ [dr.shaw@me.com](mailto:dr.shaw@me.com))

Chang Gung Memorial Hospital <https://orcid.org/0000-0002-3931-7297>

---

## Research article

**Keywords:** First trimester, Mean arterial pressure, Placental growth factor, Preeclampsia, Uterine artery pulsatility index

**Posted Date:** August 12th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-54124/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background** First trimester screening is essential to preeclampsia (PE) prevention. Fetal Medicine Foundation (FMF) model combined maternal characteristics with mean arterial pressure (MAP), uterine artery pulsatility index (UtAPI) and placental growth factor (PIGF) to estimate risk. High detection rate (DR) was observed in Asia. The study aims to evaluate performance of screening in Taiwan.

**Methods** This was a prospective and non-interventional study between January, 2017 and June, 2018. Data was collected from 700 pregnant women at 11<sup>+0</sup>-13<sup>+6</sup> gestational week. Maternal characteristics were recorded. MAP, UtAPI and PIGF were measured and converted into Multiple of the Median (MoM). Patient-specific risks were calculated with FMF model. Performance of screening was examined by ROC curve and DR.

**Results** 25 women (3.57%) contracted PE, including 8 with preterm PE (1.14%). In preterm PE, mean MoM of MAP and UtAPI were higher (1.096 vs 1.000; 1.084 vs 1.035). Mean MoM of PIGF was lower (0.927 vs 1.031). DR in preterm PE achieved 12.5%, 50.0%, 50.0% and 62.5% at false-positive rate (FPR) of 5%, 10%, 15% and 20%.

**Conclusion** FMF model showed high DR for PE in Taiwan. Integration of PE and Down screening could set up a one-step workflow.

## Background

Preeclampsia (PE) affects about 1–2% pregnancies in Taiwan [1]. This hypertensive syndrome that occurs during pregnancy results in real risk of maternal and perinatal health [2]. The negative impact on mother and fetus is more hazardous in preterm PE (delivery  $\leq$  37th week of gestation) [3]. To avoid preterm delivery and its complications, adequate prevention in early gestation is needed [4]. Aspirin for Evidence-Based Preeclampsia Prevention trial (ASPREE) demonstrated that low-dose Aspirin (150 mg/day) significantly reduced the incidence (50%) of PE in high-risk women [5]. Moreover, a systematic review and meta-analysis reported that prophylactic use of Aspirin (100 mg/day) at < 16th week of gestation substantially lessened the risk (65%) of preterm PE [6]. Consequently, early identification of high risk of PE is essential to proper prevention.

Traditional screening for PE is based on maternal characteristic and medical history defined by professional associations. The National Institute for Health and Care Excellence (NICE) recommends women with one high-risk factor or two moderate-risk factors take Aspirin (75 mg/day) at 12th week of gestation [7]. The American College of Obstetricians and Gynecologists (ACOG) recommends women with one high factor or two moderate factors take Aspirin (81 mg/day) at 12th -28th week of gestation [8]. However, both models showed insufficient power for PE screening in a recent research [9]. Extensive studies were dedicated to identifying promising biomarkers to predict PE at 11<sup>+0</sup>-13<sup>+6</sup> week of gestation. Mean arterial pressure (MAP), uterine artery pulsatility index (UtAPI) and placental growth factor (PIGF) appeared to be the most powerful for first trimester screening [10]. As a result, a novel model (FMF triple

test) developed by FMF combined maternal characteristics with biophysical and biochemical factors to estimate patient-specific risk based on Bayes theorem [11]. A recent study in Asian population showed the performance of FMF triple test is superior to those of NICE and ACOG [12]. The objective of this study is to evaluate the performance of FMF triple test and set up a standard protocol for first trimester screening of PE in Taiwan.

## Methods

This was a prospective, single-center and non-interventional cohort study between January 1st, 2017 and June 30th, 2018 at Taipei Chang Gung Memorial Hospital in Taiwan. Data was derived from routine examination of 700 women with singleton pregnancies at 11<sup>+0</sup>-13<sup>+6</sup> week of gestation. Written informed consent was obtained from all eligible women for participation. This study was approved by Chang Gung Medical Foundation Institutional Review Board (CGMF Ref. No. 201601672B0 and No. 103-5484B).

## Participants

Inclusion criteria were  $\geq 18$  years old women with singleton pregnancy at 11<sup>+0</sup>-13<sup>+6</sup> week of gestation undergoing first-trimester screening and subsequently delivering a live birth or stillbirth at  $\geq 24$ th week of gestation. Gestational age was measured with fetal crown-rump length [13]. Pregnancies with maternal factors, such as mental and severe illness, or fetal abnormality diagnosed at the time of screening were excluded from the study.

## Procedures

Through prenatal examination at 11<sup>+0</sup>-13<sup>+6</sup> week of gestation, maternal characteristics and medical histories were recorded [14]. MAP was measured according to standardized protocol by validated automated devices (BP3AQ1 Microlife, Taipei, Taiwan) [15]. UtAPI was obtained from left and right uterine arteries through pulsed-waved Doppler ultrasound imaging [16]. All operators had received Certificate of Competence from FMF. PIGF in serum was measured by automated analyzer, B•R•A•H•M•S KRYPTOR analyzer (ThermoFisher Scientific, Hennigsdorf, Germany). All investigators were provided with training for all procedures in advance. Consistent collection of data was maintained throughout study period.

## Outcome Measures

Pregnancy outcome was collected from general practitioners of women or hospital maternity records. Based on the definition from ACOG, PE was diagnosed by preexisting or pregnancy-associated hypertension [7]. Preterm and term PE were defined with delivery with PE at  $\leq 37$ th and  $> 37$ th week of gestation, respectively [17].

# Statistical analysis

To normalize the data from FMF triple test, measured values of MAP, UtAPI and PIGF were converted into MoM. East Asian-specific biomarkers MoM formula was determined by multivariate regression analysis of maternal characteristics contributing substantively to  $\log_{10}$  transformed value [18]. MoM values of MAP, UtAPI and PIGF in unaffected, all, preterm and term PE group were analyzed by one-way ANOVA.

Based on Bayes theorem-based model from FMF, patient-specific risks of PE were calculated by a combination of maternal characteristics and MoM values of three biomarkers with the software of astraia (version 1.26.1) [19–21]. Performance of screening for PE by FMF triple test was assessed by examining the ability to discriminate between PE and non-PE group [22]. Area under the receiver operating characteristic (AUROC) and detection rate (DR) at fixed false-positive rate (FPR) of 5%, 10%, 15% and 20% were utilized to evaluate discrimination. Regarding statistical software, Prism version 8.0.1 (GraphPad Software Inc., San Diego, CA, USA) was used for data analysis and receiver operating characteristic (ROC) curve analysis.

## Results

### Distribution of biomarkers

Of 700 pregnancies in the study, 3.57% (25 of 700) of the cases experienced PE. The incidences of all, preterm and term PE were 3.57%, 1.14% and 1.85%, respectively. Comparison of MoM of three biomarkers was shown in Fig. 1. The mean MAP MoM of women with preterm 1.096 (95% confidence interval [CI], 1.025–1.166), all PE 1.073 (95% CI, 1.030–1.117) and term PE 1.063 (95% CI, 1.003–1.122) were higher than that without PE 1.000 (95% CI, 0.994–1.007) with no significant difference. The mean UtAPI MoM of women with preterm 1.084 (95% CI, 0.809–1.360), all PE 1.078 (95% CI, 1.960–1.195) and term PE 1.075 (95% CI, 0.935–1.215) were higher than that without PE 1.035 (95% CI, 1.008–1.063) with no significant difference. The mean PIGF MoM of women with preterm 0.927 (95% CI, 0.632–1.223), all PE 0.975 (95% CI, 0.851–1.099) and term PE 0.997 (95% CI, 0.852–1.142) were lower than that without PE 1.031 (95% CI, 0.992–1.070) with no significant difference.

### Performance Of Screening

To evaluate the performance of screening for PE, AUROC and DR of model are effective indicators. Comparison of DR at different FPR was showed in Table 1. ROC curve of screening for all, preterm and term PE were shown in Fig. 2. For screening of all PE, FMF triple test had an AUROC of 0.7330 (95% CI, 0.6479–0.8182) and DR of 8.0%, 20.0%, 32.0% and 48.0% at FPR of 5%, 10%, 15% and 20%. These results corresponded to risk cut-offs of 1 in 50, 1 in 98, 1 in 153 and 1 in 213, respectively. For screening of preterm PE, FMF triple test had an AUROC of 0.7876 (95% CI, 0.6482–0.9270) and DR of 12.5%, 50.0%, 50.0% and 62.5% at FPR of 5%, 10%, 15% and 20%. These results corresponded to risk cut-offs of 1 in 50,

1 in 98, 1 in 152 and 1 in 208, respectively. For screening of term PE, FMF triple test had an AUROC of 0.7016 (95% CI, 0.5990–0.8041) and DR of 5.9%, 11.8%, 17.7% and 41.2% at FPR of 5%, 10%, 15% and 20%. These results corresponded to risk cut-offs of 1 in 50, 1 in 97, 1 in 146 and 1 in 208, respectively.

Table 1  
Performance of screening of all, preterm and term PE.

FPR, %	Risk cut-off (1 in x) <sup>a</sup>	DR, %	Confidence interval, %
All PE			
5%	50	8.00	1.42–24.97
10%	98	20.00	8.86–39.13
15%	153	32.00	17.21–51.59
20%	213	48.00	30.03–66.50
Preterm PE			
5%	50	12.50	0.64–47.09
10%	98	50.00	21.52–78.48
15%	152	50.00	21.52–78.48
20%	208	62.50	30.57–86.32
Term PE			
5%	50	5.88	0.30–26.98
10%	97	11.76	2.09–34.34
15%	146	17.65	6.19–41.03
20%	208	41.18	21.61–63.99
DR Detection rate; FPR False-positive rate; PE Preeclampsia.			
<sup>a</sup> “x” indicates number in the column. A screen positive test indicates women with risk more than “1 in x”.			

## Discussion

### Biomarkers for screening of preterm PE

Our PIGF levels were specifically lower in both preterm and term PE groups. Consistent with previous study, the East Asian have lower PIGF level than the Caucasian because of their smaller placental size, that might lead to high FPR and poor performance of screening [23].

Standardization of acquiring biomarker was essential to improve performance of screening. In previous study in Chinese population, lower DR was noted due to improper measurement of blood pressure and pulsatility index without FMF protocol [24]. Therefore, training for all procedure according FMF criteria was provided in advance to obtain precise data in our study.

## Performance In Screening Of Preterm PE

Consistent with previous studies in Asian population, FMF triple test achieved high DR of 12.5%, 50.0%, 50.0% and 62.5% at FPR of 5%, 10%, 15% and 20% in Taiwan [12]. Nonetheless, screening performance of PE in Asia was inferior to that in Europe [9]. First, frequency of PE and risk factor were lower in the Asian. These geographic differences might be derived from living standard, accessibility to healthcare and sociodemographic factors [25].

Compared with ACOG and NICE model, FMF triple test had better performance in screening of PE, that was consistent in Asian and European populations [9, 12]. ACOG and NICE treated each maternal characteristic as a separated test with FPR and additive detection. However, FMF calculated prior risk with multivariate regression analysis of maternal characteristics. Then, Patient-specific risks were generated with different relative importance from every maternal characteristic and adjustment according to biophysical and biochemical factors [14].

## Implication Of Clinical Practice

Taiwanese pregnant women are requested to attend for their routine first antenatal visit at 11<sup>+0</sup>-13<sup>+6</sup> week of gestation. Maternal characteristics and medical history were recorded based on the guideline from FMF. MAP could be measured by healthcare assistants with minimal training according to the protocol. The procedure merely took a few minutes with an inexpensive equipment. UtAPI should be measured by same qualified sonographers and ultrasound machines. Only additional 2–3 minutes beyond original test of Down screening (around 10 minutes) were needed to scan the flow of uterine artery. PIGF in serum could be measured with same blood sample and automated platform of associated plasma protein-A and  $\beta$ -human chorionic gonadotropin, important biochemical factors in screening of Down syndrome [26]. The calculation of patient-specific risk for PE was available with the software astraia. All components of PE screening were similar with those of Down screening which were well developed for a long time. With good performance of this study, first trimester screening for PE has been regularly implemented in our hospital. High compliance was noted because of no excessive intervention for pregnant women. As the second reason of maternal death in pregnancy, early prediction of PE was suggested by special bodies. Therefore, integration of PE and Down screening could generate a one-step workflow as daily practice in Taiwan.

## Strengths And Limitations

This is the first study for evaluation of first trimester screening of PE in Taiwan. Maternal characteristics and medical histories were prospectively collected from routine examination in a specific GA range. All biomarkers were acquired with standardized approaches and converted into MoM based on East Asian-specific formula. As a result, screening model was properly applied to estimate patient-specific risk of PE.

Our participants represented a relatively small sample size. Model overfitting might happen due to data collection from only single center. Besides, some participants were prescribed Aspirin (100 mg/day) due to predictable elevated risk of PE based on their maternal characteristics. With the treatment of Aspirin, some screen-positive participants might be transformed into false-positives, that might reduce the DR of model.

## Conclusion

For proper prophylaxis of Aspirin, effective screening of PE is indispensable in first trimester. Consistent with previous study in Asia, FMF triple test showed high DR for preterm PE in Taiwan. First Taiwan prospective and non-interventional study to screen the preeclampsia in first trimester pregnancy showed the effective workflow for daily practice.

## Abbreviations

ACOG: American College of Obstetricians and Gynecologists; CI: Confidence interval; DR: Detection rate; FPR: False-positive rate; FMF: Fetal Medicine Foundation; MAP: Mean arterial pressure; MoM: Multiple of the median; PIGF: Placental growth factor; NICE: National Institute for Health and Care Excellence; PE: Preeclampsia; UtAPI: Uterine artery pulsatility index.

## Declarations

### Ethics approval and consent to participate

This study was approved by Chang Gung Medical Foundation Institutional Review Board (CGMF Ref. No. 201601672B0 and No. 103-5484B). Written informed consent were obtained from all eligible participants.

### Consent for publication

Not applicable.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors declare that they have no competing interests.

## Funding

The authors declare that they receive no funding.

## Authors' contributions

YTC and SWS designed the study. YTC, PJC, HYH and SWS collected the data. TYL and SWS analyzed the data. YTC and TYL drafted the manuscript. KSC and SWS revised the manuscript. SWS conducted critical review. All authors were involved in the amendment and approval of final manuscript.

## Acknowledgements

This work was supported to Steven W. Shaw who is the PI by Chang Gung Memorial Hospital grant CMRPG3D1683, CMRPG3G0181 and Ministry of Science and Technology Taiwan grant MOST 108-2314-B-182A-085. We thank Bionet Corp. and Thermal Fisher Scientific BRAHMS KRYPTOR for supporting the reagents of PIGF.

## References

1. You, S.H., et al., *Population-based trends and risk factors of early- and late-onset preeclampsia in Taiwan 2001-2014*. BMC Pregnancy Childbirth, 2018. **18**(1): p. 199.
2. Mol, B.W.J., et al., *Pre-eclampsia*. Lancet, 2016. **387**(10022): p. 999-1011.
3. Johnson, A., et al., *[192-POS]: Term and preterm preeclampsia: Are there two distinct phenotypes?* Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 2015. **5**(1): p. 97.
4. Meher, S., et al., *Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis*. Am J Obstet Gynecol, 2017. **216**(2): p. 121-128.e2.
5. Rolnik, D.L., et al., *Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia*. N Engl J Med, 2017. **377**(7): p. 613-622.
6. Roberge, S., E. Bujold, and K.H. Nicolaidis, *Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis*. Am J Obstet Gynecol, 2018. **218**(3): p. 287-293.e1.
7. *Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy*. Obstet Gynecol, 2013. **122**(5): p. 1122-31.
8. *ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy*. Obstet Gynecol, 2018. **132**(1): p. e44-e52.
9. O'Gorman, N., et al., *Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations*. Ultrasound Obstet Gynecol, 2017. **49**(6): p. 756-760.

10. O'Gorman, N., et al., *Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation*. Am J Obstet Gynecol, 2016. **214**(1): p. 103.e1-103.e12.
11. Poon, L.C., et al., *The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention*. Int J Gynaecol Obstet, 2019. **145 Suppl 1**(Suppl 1): p. 1-33.
12. Chaemsaihong, P., et al., *Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population*. Am J Obstet Gynecol, 2019. **221**(6): p. 650.e1-650.e16.
13. Sahota, D.S., et al., *Fetal crown-rump length and estimation of gestational age in an ethnic Chinese population*. Ultrasound Obstet Gynecol, 2009. **33**(2): p. 157-60.
14. Wright, D., et al., *Competing risks model in screening for preeclampsia by maternal characteristics and medical history*. Am J Obstet Gynecol, 2015. **213**(1): p. 62.e1-62.e10.
15. Roberts, L., et al., *Protocol for measurement of mean arterial pressure at 10-40weeks' gestation*. Pregnancy Hypertens, 2017. **10**: p. 155-160.
16. Plasencia, W., et al., *Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia*. Ultrasound Obstet Gynecol, 2007. **30**(5): p. 742-9.
17. Brown, M.A., et al., *The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)*. Hypertens Pregnancy, 2001. **20**(1): p. ix-xiv.
18. Tan, M.Y., et al., *Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation*. Ultrasound Obstet Gynecol, 2018. **52**(2): p. 186-195.
19. Wright, A., et al., *Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history*. Ultrasound Obstet Gynecol, 2015. **45**(6): p. 698-706.
20. Tayyar, A., et al., *Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history*. Ultrasound Obstet Gynecol, 2015. **45**(6): p. 689-97.
21. Tsiakkas, A., et al., *Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history*. Ultrasound Obstet Gynecol, 2015. **45**(5): p. 591-8.
22. Wright, D., et al., *Predictive performance of the competing risk model in screening for preeclampsia*. Am J Obstet Gynecol, 2019. **220**(2): p. 199.e1-199.e13.
23. Chaemsaihong, P., et al., *First-trimester pre-eclampsia biomarker profiles in Asian population: a multicenter cohort study*. Ultrasound in Obstetrics & Gynecology. **n/a**(n/a).
24. Cheng, Y., et al., *First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study*. Bjog, 2018. **125**(4): p. 442-449.
25. Ghosh, G., et al., *Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women*. Ethn Dis, 2014. **24**(3): p. 283-9.
26. *Practice Bulletin No. 163: Screening for Fetal Aneuploidy*. Obstet Gynecol, 2016. **127**(5): p. e123-37.

# Figures




Figure 1

Box plots of MoM of MAP, UtAPI and PIGF in unaffected, all, preterm and term PE group. MAP Mean arterial pressure; MoM Multiples of the median; PIGF Placental growth factor; PE Preeclampsia; UtAPI Uterine artery pulsatility index.




Figure 2

ROC curves for screening of all, preterm and term PE. PE Preeclampsia.